A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

Recruiting Phase 2 Interventional Study
Hypertension
Ready to participate?

Review the details below, then apply to join this clinical trial.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Part A: Inclusion Criteria * Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg * Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications Part B: Inclusion Criteria…
Contacts

Alnylam Clinical Trial Information Line

1-877-ALNYLAM

clinicaltrials@alnylam.com

CONTACT

Alnylam Clinical Trial Information Line

1-877-256-9526

clinicaltrials@alnylam.com

CONTACT